Shares of Nevro Corp (NYSE:NVRO) have been assigned a consensus rating of “Hold” from the fourteen ratings firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $64.64.

Several research analysts have commented on the company. Zacks Investment Research lowered Nevro from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. ValuEngine raised Nevro from a “sell” rating to a “hold” rating in a research report on Wednesday, March 20th. BMO Capital Markets lowered Nevro from an “outperform” rating to a “market perform” rating in a research report on Friday, February 22nd. Northland Securities reaffirmed a “hold” rating and set a $48.00 price target on shares of Nevro in a research report on Friday, January 11th. Finally, Wells Fargo & Co raised Nevro from a “market perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a research report on Wednesday, March 20th.

NVRO stock traded down $0.11 during trading on Friday, hitting $65.58. 823,571 shares of the company’s stock were exchanged, compared to its average volume of 595,753. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -39.99 and a beta of 0.21. Nevro has a 52-week low of $34.75 and a 52-week high of $94.34. The company has a quick ratio of 5.64, a current ratio of 7.11 and a debt-to-equity ratio of 0.62.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Thursday, February 21st. The medical equipment provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.15). The firm had revenue of $107.90 million for the quarter, compared to analyst estimates of $107.39 million. Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The company’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the firm earned ($0.15) EPS. As a group, sell-side analysts anticipate that Nevro will post -2.31 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVRO. Advisor Group Inc. increased its holdings in shares of Nevro by 64.5% in the fourth quarter. Advisor Group Inc. now owns 921 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 361 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of Nevro in the fourth quarter valued at approximately $113,000. HRT Financial LLC acquired a new position in shares of Nevro in the third quarter valued at approximately $208,000. Tower Research Capital LLC TRC increased its holdings in shares of Nevro by 4,723.3% in the third quarter. Tower Research Capital LLC TRC now owns 4,341 shares of the medical equipment provider’s stock valued at $248,000 after purchasing an additional 4,251 shares during the period. Finally, Cerebellum GP LLC acquired a new position in shares of Nevro in the fourth quarter valued at approximately $177,000.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: Why are gap-down stocks important?

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.